COMMUNIQUÉS West-GlobeNewswire

Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol “PLYX”
02/02/2026
PARAMUS, NJ, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (“Polaryx” or the “Company”) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of novel, disease- [...]
Spectral AI to Participate in National Burn Awareness Week 2026 February 1–7, 2026
02/02/2026
DALLAS, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”) , an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment [...]
Sparrow Appoints Biopharmaceutical Industry Veteran, Carlo Incerti, M.D. to its Board of Directors
02/02/2026
BOSTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sparrow Pharmaceuticals , a targeted cardiometabolic therapeutics company, today announced the appointment of Carlo Incerti, M.D., to its Board of Directors, effective January 1 [...]
Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care
02/02/2026
Management to Engage with Global Clinical Research Leaders Ahead of Phase 2a Trial of Concussion Treatment Sarasota, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) (“the “Company”), a [...]
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026
02/02/2026
- Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron ® treatment to be well tolerated - ATLANTA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: [...]
CorMedix Therapeutics Announces Share Repurchase Program
02/02/2026
BERKELEY HEIGHTS, N.J., Feb. 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases [...]
Standard Dental Labs Announces Acquisition of BRLIT Dental Laboratory, Inc.
02/02/2026
ORLANDO, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Standard Dental Labs Inc. (“SDL”), a Florida-based dental laboratory platform focused on high-quality clinical outcomes and long-term practitioner relationships, today [...]
SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA
02/02/2026
NeuroThera’s Proprietary Cannabinoid-Enhanced Platform Targets Antibiotic Resistance Using Approved Antimicrobials TEL AVIV, Israel, Feb. 02, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc [...]
Quotient Therapeutics Appoints Seasoned Life Sciences Executive, Susan Keefe, as Chief Financial Officer
02/02/2026
CAMBRIDGE, Mass. and CAMBRIDGE, United Kingdom, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Quotient Therapeutics, a company pioneering somatic genomics to inform breakthrough medicines, today announced that it has appointed [...]
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026
02/02/2026
CONSHOHOCKEN, Pa., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its fourth-quarter and full-year 2025 financial results on Thursday, Feb. 19, 2026 [...]
60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership
02/02/2026
GoodRx to offer prescription savings of up to 30% for ARAKODA ® ( tafenoquine ) Collaboration designed to lower patient out-of-pocket costs and expand the reach of Company’s marketing strategy Partnership will improve [...]
Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026
02/02/2026
RESEARCH TRIANGLE PARK, N.C., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore [...]
Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency
02/02/2026
WVE-006 is a first-in-class RNA editing therapeutic candidate designed to correct the root cause of disease for the 200,000 individuals in the U.S. and Europe living with AATD; no currently approved therapies address [...]
EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg
02/02/2026
EURneffy 1 mg will be the first and only needle-free adrenaline available to younger children in the European Union ARS Pharma’s partner, ALK-Abelló A/S, who owns the rights to market EURneffy in the EU, will distribute [...]
Hydreight Technologies Issues Fiscal 2026 Revenue Guidance of ≈ $150 Million and Provides Q1 2026 Outlook
02/02/2026
VANCOUVER, British Columbia, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6) (“Hydreight” or the “Company”), a provider of compliant digital health infrastructure and [...]
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis
02/02/2026
Publication includes a systematic review of 24 studies describing off-label cutaneous application of statins in porokeratosis Preliminary case reports suggesting clinical benefit underscore unmet need for development of [...]
Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026
02/02/2026
CELEBRATION, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, [...]
Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth
02/02/2026
Doubling of VEVYE® Sales Force is On Track, Expansion of IHEEZO® Commercial Footprint to the Office-Based Setting Underway, and Doubling TRIESENCE® Commercial Footprint in the Surgical-Based Setting is Proceeding [...]
Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™
02/02/2026
Deficiencies limited to packaging and administration Company believes it can rapidly resolve deficiencies and expects to resubmit as early as Q3 2026 Remains well-capitalized and anticipates ending 2026 with significant [...]

Pages